Janssen Biotech, Inc.

Centocor, Inc.

Mallinckrodt Hospital Products IP Limited

Centocor Ortho Biotech Inc.

Other

Mallinckrodt Pharmaceuticals Ireland Limited

Therakos, Inc.

Centocor Research & Development, Inc.

Ortho Biotech Holding LLC

David Peritt

David M Knight

Jill M Giles-Komar

Bernard Scallon

David J Shealy

Jinquan Luo

George A Heavner

Mohit Trikha

Geoffrey Phillip Symonds

Janet Lesley Macpherson

Philip Wong

Kevin Henrichsen

Susan Pond

Kim Campbell

Amy Krutsick

Bernhard Scallon

Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell ('APC'), has a high capacity to do so. The recognition of apoptotic cells ('ACs') occurs via a series of evolutionarily-conserved, AC associated molecular-pattern receptors (&#x201c;ACAMPRs&#x201d;) on APCs that recognize and bind corresponding apoptotic-cell-associated molecular patterns (&#x201c;ACAMPs&#x201d;). These receptors recognize ligands such as phosphotidyl serine and oxidized lipids found on apoptotic cells. Savill et al. (2002); and Gregory et al. (2004).

Use of apoptotic cells ex vivo to generate regulatory T cells

Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as systemic lupus erythematosus.

Method for treating lupus by administering an anti-IL-12 antibody

Methods (), devices, and systems of processing blood are described. The method () comprises the steps of: obtaining () blood from a patient coupled to a single blood processing device to form a closed loop between the patient and the blood processing device; collecting () bulk mononuclear blood cells from the blood by leukapheresis implemented using the blood processing device in the closed loop; and enriching () concurrently target cells separated from non-target cells in the bulk mononuclear blood cells using the blood processing device in the closed loop.

Processing blood

Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis.

An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Method of treating lupus by administering an anti-IL-12 antibody

Anti-IL-12 antibodies and compositions

Nucleic acids encoding anti-IL-12 antibody

Method of treating Crohn's disease by administering an anti-IL-12 antibody

Method for treating psoriasis by administering an anti-IL-12 antibody

An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in treating IL-12-related disorders, such as psoriatic arthritis.

Method for treating psoriatic arthritis by administering an anti-IL-12 antibody

Growing community of inventors

Bala Cynwyd, PA, United States of America

David Peritt